The Company is also engaged in creating an affordable, world class healthcare delivery system for the middle and lower income-group people, in one of the states of the country. It will be an integrated network of Hub-and-spoke hospitals with a total capacity of 1000 beds across 7 hospitals and 2 nursing schools, in West Bengal.Through its subsidiary Jubilant First Trust Healthcare it will provide a combination of professional, efficient, cutting-edge technology based, international standard healthcare services model that will bridge the significant gap in the healthcare delivery mechanism for the larger section of the community.

A 120 bed super specialty facility, Jubilant Kalpataru Hospital was recently opened in Barasat, Kolkata. The Company is endeavoring to provide access to quality healthcare for the people at the bottom of the pyramid, who so far do not have the privilege of affordable healthcare.

In its quest to enable partners with focused and targeted therapy, the DDDS group partners Jubilant First trust (health care delivery group)with globally renowned academia to identify potential biomarkers and new targets that will improve development efforts while reducing the cost of therapy. Cohort studies to understand chronic disease pattern in Indian population compared with the other global genetic diaspora is an effort at DDDS to better understand disease biology and develop druggable targets focusing on unmet needs.

Jubilant’s Value proposition to big pharma and biotech is

• Providing high quality and low cost drug discovery and development services for expanding pipeline of innovative products
• Offering products from pre- clinical to clinical, intermediate to finished products at speedier, high quality lower cost
• Offering contract manufacturing services at substantially lower cost than their internal cost with high quality and on time deliveries
• Providing complete life cycle management from pre to post patent expiry of innovative products